Raxibacumab
Raxibacumab is a monoclonal antibody medication used to treat inhalation anthrax, including cases complicated by toxin presence. It works by binding to and neutralizing the protective antigen of Bacillus anthracis, preventing the anthrax toxin from damaging cells. This treatment is typically reserved for situations where standard antibiotic therapy is inadequate or not appropriate.
Raxibacumab is a monoclonal antibody treatment for inhalation anthrax that neutralizes anthrax toxin by binding to its protective antigen.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- J06BC02
- RxNorm
- 1366567
- Generic
- Raxibacumab
- Class
- atc-j06
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
all trimestersavoid unless benefits outweigh risks
use only if clearly needed for anthrax treatment when no alternatives available
regular fetal monitoring including ultrasound assessments
Use with caution and monitor for adverse effects.
lactation
breastfeedingno adjustment recommended
decision to discontinue breastfeeding or discontinue drug should consider importance of drug to mother; monitor infant for adverse effects
observe infant for signs of infection or immune system effects
geriatric
elderly 65 and olderno specific dose adjustment required
use standard adult dosing; monitor renal and hepatic function
standard monitoring for adverse effects; assess organ function
pediatric_age
pediatrics under 18safety and efficacy not established
not recommended for use in pediatric patients due to lack of safety data; consider alternative treatments
no specific monitoring guidelines available
renal_impairment
mild to moderateno dose adjustment required
no dose adjustment needed; monoclonal antibodies are not eliminated by renal clearance
standard clinical monitoring
renal_impairment
severeno dose adjustment required
use standard adult dosing; monitor closely for infusion reactions
standard infusion monitoring
hepatic_impairment
mild to moderateuse with caution
use with caution; monitor liver function tests
monitor hepatic function parameters before and during treatment
Use with caution and monitor for adverse effects.
hepatic_impairment
severeuse with extreme caution
use only if benefits clearly outweigh risks; consider alternative therapies
close hepatic function monitoring; assess for worsening function
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Biological product classification
Common uses
Therapeutic indication
FDA approval year
Regulatory approval information
Mechanism of action
Pharmacological mechanism
Treatment of inhalation anthrax caused by Bacillus anthracis, particularly when toxin-mediated complications are present or suspected. It is used when alternative treatments are not suitable.
Raxibacumab is a recombinant monoclonal antibody that specifically binds to the protective antigen (PA) of B. anthracis. By binding to PA, it prevents the formation of the anthrax toxin complex, thereby neutralizing its effects and protecting cells from toxin-mediated damage.
Administered intravenously; should be used in conjunction with appropriate antibacterial drugs for systemic anthrax infection. Safety and efficacy established primarily through animal studies due to ethical constraints. May cause infusion-related reactions.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy